CVS CVS Health Corporation : Bullish and Bearish Analyst Opinions

CVS earnings can grow to $10 EPS.

Insurers providing private Medicare Advantage plans rose after the U.S. agreed to boost 2027 payments by almost 2.5% more than the initial proposal. The rate increase may allow companies to expand margins next year if they continue reducing benefits and managing expenses. Positive for stock prices due to improved revenue outlook and relief from federal cost-cutting pressures. If companies fail to effectively manage expenses or benefit reductions, margin expansion might not materialize.

The US government finalized a +2.5% payment increase for private Medicare plans (Medicare Advantage) in 2027, an improvement over the initial proposal and above expectations of ~1%. This affects roughly half a trillion dollars in spending. The higher rate helps insurers cover rising healthcare costs, supporting profitability and sustainability of their Medicare businesses. A positive regulatory outcome for major managed care companies, driving significant pre-market share price gains (UnitedHealth +10%, CVS +5%). Political rhetoric from President Trump questioning affordability of Medicare/Medicaid could lead to future payment pressure.

The 2.48% Medicare rate increase applies to Aetna (owned by CVS Health), beating Wall Street's 1-1.5% expectations. The $13 billion industry-wide payment boost provides a direct revenue tailwind for Aetna's Medicare Advantage business. The regulatory win provides a strong fundamental catalyst for CVS's insurance arm. Ongoing scrutiny over risk scores and coding practices by the Medicare agency.

The speaker explicitly listed CVS among the "big insurance companies" benefiting from the Medicare Advantage rate decision. CVS (via its Aetna business) is a significant participant in the Medicare Advantage market. The better-than-feared rate hike removes a major overhang on the profitability of this segment. LONG because the company is identified as a winner from the policy reversal, which should support its integrated health services model. Similar to peers, the long-term risk is regulatory pressure to reduce costs within the Medicare Advantage program.

Management's strategic shift from net closures to net openings signals a positive inflection point for the business and potential for revenue growth recovery.

A caller asked about Oddity (ODD) after a bad quarter. When a growth stock breaks (bad quarter), you don't buy the dip immediately. You rotate into high-quality incumbents with cash flow. Avoid ODD, buy ULTA or CVS for stability. Consumer spending slowdown affecting retail/pharmacy.

Senator Marshall explicitly mentioned "clipping the wings of the Pharmacy Benefit Managers (PBMs)" and codifying "Trump Rx" / price transparency. PBMs (owned by major insurers like CVS, Cigna, UnitedHealth) rely on opaque pricing models for profit. Legislative momentum to force transparency or reduce their leverage acts as a regulatory headwind for these specific healthcare verticals. WATCH / AVOID PBM-exposed healthcare stocks. Gridlock in Congress prevents legislation from passing.

The administration is pushing a healthcare framework that looks to "shift federal subsidies from the insurance companies to consumers." Managed Care Organizations (MCOs) rely heavily on federal subsidies (Medicare Advantage, etc.) for margin. Direct-to-consumer subsidies bypass the insurers, potentially squeezing their margins and reducing their role as intermediaries. SHORT large cap insurers heavily exposed to government programs. The healthcare lobby is powerful and may water down or block the transfer of subsidy mechanics.

Schneider explicitly highlights the "extension of the premium tax subsidies" as a priority, warning that without it, "millions of families are seeing their insurance increase by $1,500 a month." These subsidies (enhanced ACA tax credits) are direct revenue drivers for Managed Care Organizations (MCOs) focused on the exchange market. Schneider's push indicates that Democrats will make extending these credits a non-negotiable condition in budget talks. If extended, enrollment numbers for Centene, Molina, and others remain robust; if they lapse, churn increases and revenue drops. LONG. The political pressure to avoid an $18k/year cost spike for voters is high, favoring an eventual extension which benefits ACA-heavy insurers. Republican opposition to "pandemic-era" subsidy extensions could lead to a lapse, crushing margins for exchange-focused insurers.

The President intends to "codify his health care framework that seeks to shift federal subsidies from health care companies to U.S. consumers." Managed Care Organizations (MCOs) and insurers rely heavily on government subsidies (particularly in Medicare Advantage). Shifting these funds directly to consumers bypasses the insurers, threatening their margins and revenue models. SHORT. This represents a structural change to healthcare funding flows detrimental to intermediaries. The complexity of healthcare reform often leads to watered-down implementation.

"82,000 jobs from health care... That's 95% of the jobs that were added... It's a trend that we've continued to see because of demographic changes." The host questions the quality of this growth, but Yared defends it as structurally necessary due to an "aging society." If 95% of labor demand is in this sector, it indicates where revenue and utilization are actually expanding in a slowing economy. LONG. Healthcare providers and services are the only sector showing recession-proof volume growth in this data set. Regulatory changes or reimbursement rate cuts could impact profitability despite high volume.

Medical distributors and managed care are performing well. * McKesson (MCK) & Cardinal Health (CAH): "Classic drug middlemen." They are consistent winners; buy them anytime they dip. * CVS Health (CVS): The only health insurer to own. It is now the last real national drugstore chain (with Walgreens private and Rite Aid closed) and is undervalued as a managed care play.

The administration proposed a "0.09% next year" payment increase. Holz notes investors were "positioning long thinking this was going to be a turnaround year," but now we are entering a "pocket now for a year, maybe two, in which earnings don't expand or grow." The macro environment for government-sponsored healthcare has shifted from a growth story to a stagnation story. While the stocks have dropped 20%, the fundamental driver for stock price appreciation (earnings growth) has been removed for the medium term. Buying the dip is premature because the capital will be tied up in a sector with no catalyst for 12-24 months. Do not buy the dip yet. The thesis has shifted from "turnaround" to "stagnation." The final ruling in April could be revised upward significantly, causing a relief rally (short squeeze).

great article. social contracts in markets is one thing, but you're also seeing it collapse re: civil liberties, esp. in europe, etc. saw a post yesterday talking about how americans didn't grow up wi

1. THE FACT: Cramer is "Ready to roll with Nvidia, Pepsico, CVS all the rest". 2. THE BRIDGE: This indicates these stocks are on his radar for discussion or analysis, suggesting they might be subjects of upcoming segments or have recent developments worth noting. It's not a direct buy/sell, but a signal of focus. 3. THE VERDICT: These tickers are on Cramer's immediate agenda for discussion.